Associate Professor Michael Dickinson is the Lead of the Aggressive Lymphomacancers of the lymphatic system disease group within Clinical Haematologythe study of blood and related diseases at Peter MacCallum Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs Centre and Royal Melbourne Hospital. He specialises as a principal investigator in phase I/II clinical trialsresearch studies performed to test new treatments, tests or procedures and evaluate their effectiveness on various diseases of new anticancer drugs with a current focus on Aggressive Lymphomas and novel immunotherapies, but with experience across a breadth of haematological malignancies. His investigator-initiated studies have focused on the role of epigenetic modifiers in haematological malignancies, eltrombopag as a supportive care agent in MDS/AML, and new CART therapies. Michael’s clinical research includes industry and investigator-led trials in aggressive lymphoma, phase 1 studies, and CART trials.
Michael prides himself on providing thorough and personal care to his patients throughout their cancer journeywhat a person experiences/lives from the time they think they have cancer.
His current focus is:
- The continuous improvement of the lymphoma assessment service for patients with a new diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of lymphoma or a lump for investigation; delivering best in the country diagnosis and stagingthe process of determining how big the cancer is, where it started and if it has spread to other areas evaluation in collaboration with Australia’s leading haematopathology and molecular pathologythe study of disease centre, and with PET-centre physicians with a special interest in lymphoma.
- Providing the best options for patients where standard treatments fail: Australia’s largest and most comprehensive trials programme for patients with relapsed or treatment -refractory lymphoma. Our early phase trial pipeline allows patients the best opportunity to harness new targeted treatments for cell signalling in lymphoma, and immunotherapies. At Peter Mac, our special expertise is in the development of the BCL-2 inhibitors (eg venetoclax), epigenetic therapies, T-cell activating medications, and CART.
- Providing new treatment options for patients with T-cell lymphoma.
- Building our CAR T program, both as a standard of care (if public funding is approved) and also providing CAR T trial options for patients with lymphoma.
Location
305 Grattan Street, Melbourne VIC, Australia
